期刊文献+

ICU耐碳青霉烯类抗菌药物鲍曼不动杆菌肺部感染危险因素分析 被引量:9

Analysis of Risk Factors for Lung Infection of CRAb in ICU
原文传递
导出
摘要 目的:探讨重症监护室(ICU)耐碳青霉烯类抗菌药物鲍曼不动杆菌(CRAb)肺部感染的危险因素。方法:采用回顾性研究方法,收集宝鸡市中心医院ICU 2012年6月-2014年6月鲍曼不动杆菌(Ab)肺部感染患者105例,其中CRAb组患者81例,对碳青霉烯类抗菌药物敏感Ab(CSAb)组患者24例,对发生CRAb肺部感染的危险因素采用单因素分析及多因素Logistic多元回归分析。结果:单因素分析发现,分离出Ab前ICU住院天数、ICU总住院天数、呼吸衰竭、低蛋白血症、机械通气、机械通气天数、分离出Ab前15 d内碳青霉烯类抗菌药物的使用及联合应用抗菌药物、C反应蛋白检测异常、降钙素原检测异常与ICU CRAb肺部感染的发生显著相关;多因素分析显示,分离出Ab前ICU住院天数、分离出Ab前15 d内使用碳青霉烯类抗菌药物、分离出Ab前行机械通气、分离出Ab前患者低蛋白血症为Ab感染的独立危险因素。结论:入住ICU的高危患者,应结合危险因素,尽早采取措施,合理防治CRAb肺部感染。 OBJECTIVE:To discuss the risk factors for lung infection of CRAb in ICU,and to provide reference for clinical diagnosis and treatment. METHODS:The univariate analysis and multivariate Logistic regression analysis were conducted with the method of case-control study,in which the clinical data of 105 cases of lung infection of CRAb in ICU were collected from our hospital during Jun. 2012 to Jun. 2014,with the 81 cases of CRAb and 24 cases of CSAb. RESULTS:The univariate analysis showed that those factors were significantly correlated with lung infection of CRAb in ICU,such as ICU hospitalization days before isolation of Ab,total stay in ICU,respiratory failure,hypoproteinemia,mechanical ventilation,mechanical ventilation days,the application of carbapenem antimicrobial agents and combined use of antimicrobial agents within 15 days before isolation of Ab,abnormal C-reactive protein detection,abnormal procalcitonin detection. The multivariate analysis showed that ICU hospitalization days before isolation of Ab,the application of carbapenem antimicrobial agents within 15 days before isolation of Ab,mechanical ventilation,hypoproteinemia were the independent risk factors of CRAb. CONCLUSIONS:Based on risk factors,the measures should be taken for high-risk patients as soon as possible in ICU to prevent and treat lung infection of CRAb.
出处 《中国药房》 CAS 北大核心 2015年第29期4077-4079,共3页 China Pharmacy
关键词 鲍曼不动杆菌 耐碳青霉烯 危险因素 Acinetobacter baumannii Carbapenem-resistant Risk factor
  • 相关文献

参考文献17

  • 1National Nosocomial Infections Suveillance(NNIS)System.report data summary from January 1992 though June2004,issued October 2004[J].Am J Infect Control,2004,32(8):470.
  • 2肖永红,李兰娟.卫生部全国细菌耐药监测(Mohnarin)报告[M].天津:天津科学技术出版社,2013:226.
  • 3Peleg AY,Seifert H,Paterson DL.Acinetobacterbaumannii:emergence of asuccessful pathogen[J].Clin Microbiol Rev,2008,21:538.
  • 4Kuo SC,Chang SC,Wang HY,et al.Emergence of extensively drug resistant Acinetobacterbaumannii complex over 10 years:Nationwide date from the Taiwan data from the taiwan surveillance of antimicrobial resistance(TSAR)program[J].BMC Infect Dis,2012,28(12):200.
  • 5Zheng YL,Wan YF,Zhou LY,et al.Risk factorsandmortalityof patients with nosocomial carbapenem-resistant Acinetobacterbaumannii Pneumonia[J].Am J Infect Control,2013,41(7):e59.
  • 6Dent LL,Marshall DR,Pratap S,et al.MultidrugresistantAcinetobacterbaumannii:a descriptive study in a city hospital[J].BMC Infect Dis,2010,7(10):196.
  • 7Munoz-Price LS,Robert AW.Acinetobacter Infection[J].N Engl J Med,2008,358:1 271.
  • 8Jang TN,Lee SH,Huang CH,et al.Risk factors and impact of nosocomial Acinetobacterbaumannii bloodstream infections in the adult intensive care unit:a case control study[J].J Hosp Infect,2009,73(2):143.
  • 9刘成军,龙江海,李静,许峰.儿科重症监护室27例广泛耐药鲍曼不动杆菌医院获得性肺炎的危险因素分析[J].华中科技大学学报(医学版),2013,42(2):219-222. 被引量:27
  • 10Cunha BA.Effective antibiotic resistance control strategies[J].Lancet,2001,357:1307213081.

二级参考文献36

  • 1社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量:3032
  • 2National Committee for Clinieal Laboratory Standards. Perfornance stardards for antimicrobial susceptibility testing [S].Ninth information Standard. M100-s9. Wayne,Pennsylvania:NCCLS, 1999. 100-102.
  • 3National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically[S]. Fourth Edition. Approved Standard NCCLS Document. MT-A4. Wayne, PA: NCCLS, 1997.17.
  • 4Fagon JY, Chastre J, Domart Y. Nosocomial pneumonia in patients receiving continuous mechanical ventilation[J]. Am Rev Respir Dis, 1989, 139(4):877-884.
  • 5Maragakis L L,Perl T M. Acinetobacter baumannii:epidemi ology, antimicrobial resistance, and treatment options[J]. Clin Infect Dis,2008,46(8) :1254-1263.
  • 6American Thoracic Societyllnfectious Diseases Society of A- merica. Guidelines for the management of adults with hospi- tal-acquired, ventilator-associated, and healthcare-associated pneumonia[J]. Am J Respir Crit Care Med, 2005,171 (4) : 388-416.
  • 7Chang P Y, Hsueh P R, Wu P S, et al. Multidrug resistant Acinetobactor baumannii isolates in pediatric patients of a uni- versity hospital in Taiwan[J]. J Mierobiol Immunol Infect, 2007,40(5) :406-410.
  • 8Soroush S, Haghi-Ashtiani M T,Ta.heri-kalani M, et al. Anti- microbial resistance of nosocomial strain of Acinetobacter bat~- mannii in Children's Medical Center of Tehran:a 6-year pro- spective study[J]. Acta Med Iran,2010,48(3) :178-184.
  • 9Saleem A F,Ahmed I,Mir F,et al. Pan resistant Acinetobact- er infection in neonates in Karachi, Pakistan[J]. J Infect Dev Ctries,2009,4(1) :30-37.
  • 10Sunenshine R H,Wright M O, Maragakis L L, et al. Multi- drug-resistant Acinetohacter infection mortality rate and length of hospitalization[J]. Emerg Infect Dis, 2007,13( 1 ) : 97-103.

共引文献83

同被引文献116

引证文献9

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部